EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC 4.0

Immune checkpoint inhibitor‐induced arrhythmias: Mechanistic insights from clinical and preclinical studies

Anand R Ramalingam iD, Zoltán Márton Köhler iD, Péter Ferdinandy iD, Zoltán V Varga iD

British Journal of Pharmacology · 2026-06-28

DOI: 10.1111/bph.70548 ↗

At a glance

Übersichtsarbeit in British Journal of Pharmacology, published online on 2026-06-28. Written by Anand R Ramalingam and 3 co-authors. Institution: Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary. 151 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Hungarian Academy of Sciences, European Union, Magyar Tudományos Akadémia.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and ventricular arrhythmias. These electrical disorders are not temporally constrained and can occur in isolation or alongside other cardiac complications. Clinically, ICI‐induced arrhythmias are just as significant as myocarditis and often lead to treatment interruption, hospitalisation and sudden death. Despite this, the mechanisms driving ICI‐induced electrical disturbances remain poorly understood, in part because of limited integration of clinical and preclinical insights. Here, we review emerging evidence on ICI‐induced arrhythmias and present a conceptual framework that outlines key factors in their pathogenesis, including immune‐driven injury, immune‐independent secondary amplifiers, and patient‐related susceptibility factors. Understanding these mechanistic pathways is essential for improving risk stratification, surveillance and management in patients receiving ICI therapy.

Subjects

Author keywords

AV blockCTLA‐4PD‐1PD‐L1atrial fibrillationconduction delaysventricular arrhythmias

Authors and institutions

  • Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
  • Center for Pharmacology and Drug Research and Development, Semmelweis University, Budapest, Hungary.
  • MTA-SE Momentum Cardio-Oncology and Cardioimmunology Research Group, Budapest, Hungary.
  • Pharmahungary Group, Szeged, Hungary.

ORCID profiles: Anand R Ramalingam, Zoltán Márton Köhler, Péter Ferdinandy, Zoltán V Varga

Funding

  • Hungarian Academy of Sciences
  • European Union
  • Magyar Tudományos Akadémia
  • European Commission

Cite

APA

Ramalingam, A. R., Köhler, Z. M., Ferdinandy, P., & Varga, Z. V. (2026). Immune checkpoint inhibitor‐induced arrhythmias: Mechanistic insights from clinical and preclinical studies. British Journal of Pharmacology. https://doi.org/10.1111/bph.70548

Vancouver

Ramalingam AR, Köhler ZM, Ferdinandy P, Varga ZV. Immune checkpoint inhibitor‐induced arrhythmias: Mechanistic insights from clinical and preclinical studies. British Journal of Pharmacology. 2026. doi:10.1111/bph.70548

BibTeX
@article{Ramalingam2026,
  author = {Ramalingam, Anand R and Köhler, Zoltán Márton and Ferdinandy, Péter and Varga, Zoltán V},
  title = {Immune checkpoint inhibitor‐induced arrhythmias: Mechanistic insights from clinical and preclinical studies},
  journal = {British Journal of Pharmacology},
  year = {2026},
  doi = {10.1111/bph.70548}
}
Start for free →